Article

WaveTec Vision secures additional financing

WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.

Aliso Viejo, CA-WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.

The company will use the funds to expand commercialization of its intraoperative wavefront aberrometer (ORange), demonstrate further the clinical efficacy of the technology, and increase its infrastructure, said Tom Frinzi, WaveTec chief executive officer.

The Series D financing was led by existing investor Versant Ventures, with participation from existing investors Accuitive Medical Ventures and De Novo Ventures. New investor Gund Investment Corporation also participated in the funding.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.